Generic Competition, 2007–11

Chapter 1: The Impact of Patent Expiries, 2007–11
Introduction
Patent expiry by date
Major generics companies
Overview
Europe
North America
Asia

Chapter 2: Historical and Legal Context of Generic Drugs
Impact of generics on revenue
National factors
Prozac
Plavix
Patent regulations
Europe
US

Chapter 3: Generic Biotechnology Products (Biosimilars)
Introduction
Biosimilars
Entry barriers
Major legal cases
Potential biogenerics by 2011
Legal status

Chapter 4: Major Generic Opportunities
Overview
Plavix
Advair
Lipitor

Chapter 5: Impact of Patent Expiry on Key Ethical Pharma Companies
Introduction
Abbott
Amgen
Astellas
AstraZeneca
Bayer-Schering
Boehringer Ingelheim
Bristol-Myers Squibb
Daiichi Sankyo
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Merck KGaA
Novartis
Pfizer
Roche
Sanofi-Aventis
Schering-Plough
Takeda
Wyeth

Chapter 6: Patent Expiries in 2007
Overview
Major patent expiries in Europe
Major patent expiries in the US
Potential revenue loss
Review of drugs with 2007 US patent expiries

Chapter 7: Patent Expiries in 2008 Overview
Major patent expiries in Europe
Major patent expiries in the US
Potential revenue loss
Review of drugs with 2008 US patent expiries

Chapter 8: Patent Expiries in 2009 Overview
Major patent expiries in Europe
Major patent expiries in the US
Potential revenue loss
Review of drugs with 2009 US patent expiries

Chapter 9: Patent Expiries in 2010
Overview
Major patent expiries in Europe
Major patent expiries in the US
Potential revenue loss
Review of drugs with 2010 US patent expiries

Chapter 10: Patent Expiries in 2011
Overview
Major patent expiries in Europe
Major patent expiries in the US
Potential revenue loss
Review of drugs with 2011 US patent expiries

List of Figures

Figure 1.1 2005 revenues in the US for drugs going off patent in the year indicated
Figure 1.2 Number of potential generic market entries in the US, 2007–11
Figure 1.3 Number of potential generics market entries in France, Germany and the UK, 2007–11
Figure 2.1 European generics industry showing respective market shares by value and volume in each of the five major European markets
Figure 2.2 US sales of Prozac and generic fluoxetine, 2000–05
Figure 2.3 Quarterly US sales of Plavix, 2004–06 (the figure for Q4 2006 is estimated)
Figure 5.1 Potential exposure of the 20 leading pharmaceutical companies’ revenues to generic competition, 2007–11
Figure 5.2 Potential exposure of the US revenues of the 20 leading pharmaceutical companies to generic competition by year in the period 2007–11
Figure 5.3 Expiry dates of key US drug patents by year in the period 2007–11 for the 20 leading pharmaceutical companies
Figure 6.1 US revenues at risk from patent expirations during 2007
Figure 7.1 US revenues at risk from patent expirations during 2008
Figure 8.1 US revenues at risk from patent expirations during 2009
Figure 9.1 US revenues at risk from patent expirations during 2010
Figure 10.1 US revenues at risk from patent expirations during 2011

List of Tables

Table 1.1 Leading generics companies, 2005 pro forma revenues allowing for recent acquisitions
Table 3.1 Leading biotechnology therapeutics showing reported global sales for 2004 and 2005
Table 4.1 The world’s best-selling drugs in 2005
Table 5.1 AstraZeneca products facing generic threats, 2007–11
Table 5.2 Eli Lilly products facing generic threats, 2007–11
Table 5.3 GlaxoSmithKline products facing generic threats, 2007–11
Table 5.4 Johnson & Johnson products facing generic threats, 2007–11
Table 5.5 Merck products facing generic threats, 2007–11
Table 5.6 Novartis products facing generic threats, 2007–11
Table 5.7 Pfizer products facing generic threats, 2007–11
Table 6.1 Major drugs whose patents expire in France, Germany and/or the UK in 2007
Table 6.2 Major drugs whose patent protection and marketing exclusivity expires in the US in 2007
Table 7.1 Major drugs whose patents expire in France, Germany and/or the UK in 2008
Table 7.2 Major drugs whose patent protection and marketing exclusivity expires in the US in 2008
Table 8.1 Significant drugs whose patents will expire in France, Germany and/or the UK in 2009
Table 8.2 Significant drugs whose patent protection and marketing exclusivity will expire in the US in 2009
Table 9.1 Significant drugs whose patents will expire in France, Germany and/or the UK in 2010
Table 9.2 Significant drugs whose patent protection and marketing exclusivity will expire in the US in 2010
Table 10.1 Significant drugs whose patents will expire in France, Germany and/or the UK in 2011
Table 10.2 Significant drugs whose patent protection and marketing exclusivity will expire in the US in 2011